We closed out July 2025 in Boston alongside several of our Axinn colleagues attending the American Conference Institute’s 12th Annual Summit for Women Leaders in Life Sciences Law. This conference is a highlight for us every...more
8/14/2025
/ Antitrust Litigation ,
BPCIA ,
Constitutional Challenges ,
Diversity and Inclusion Standards (D&I) ,
Drug Pricing ,
Equal Employment Opportunity Commission (EEOC) ,
Executive Orders ,
Life Sciences ,
Medical Devices ,
Pharmaceutical Industry ,
Pharmacy Benefit Manager (PBM) ,
Preliminary Injunctions ,
Women in the Law
2 In Hatch-Waxman litigation, method of treatment patents present unique infringement issues. Because generic drug manufacturers typically do not treat patients, patentees frequently allege induced or contributory...more
The FTC recently issued a policy statement warning drug manufacturers that it “intends to scrutinize improper Orange Book listings” and “use its full legal authority” to “tak[e] actions against companies and individuals that...more
10/26/2023
/ Competition ,
Department of Justice (DOJ) ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
FTC Act ,
Non-Disclosure Agreement ,
Orange Book ,
Patent Infringement ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents